Share “Star Scientific CEO, shareholders...”

Star Scientific CEO, shareholders investing $20M

Associated Press Modified: November 16, 2012 at 8:00 am •  Published: November 16, 2012

The company used to focus primarily on research of a tobacco curing process that would prevent the formation of carcinogenic toxins in tobacco. It has sold varieties of tobacco lozenges that dissolve in the user's mouth under the Ariva and Stonewall brands since 2001. But Star Scientific has shifted its focus more toward the dietary supplements it sells through its subsidiary Rock Creek Pharmaceuticals, including its Antabloc product for anti-inflammatory support and its CigRx supplement to reduce the urge to smoke.

In August, Star Scientific changed its Nasdaq ticker symbol to STSI from CIGX. Its shares closed at $1.61 in trading Thursday and have traded in a 52-week range of $1.56 to $5.05.


Michael Felberbaum can be reached at